The purpose was to evaluate the antihypertensive effect, safety and tolerability of a candesartan cilexetil/hydrochlorothiazide (16/12,5 mg) combination tablet (Candes-HCT) in patients with mild to moderate primary hypertension insufficiently controlled on previous monotherapy, in comparison with that of a losartan/hydrochlorothiazide (50/12,5 mg) combination tablet (Los-HCT).
In addition to their cardiovascular effects, calcium channel antagonists (CCA) have also been shown to decrease lower esophageal sphincter pressure and reduce esophageal motility, which may precipitate or aggravate gastroesophageal reflux disease. Thus, we hypothesized that patients who receive CCA's would have a grater frequency of acid suppressive drug use. We reviewed the pharmacy records of 16,384 hypertensive patients identified by ICD-9 401.9 from the 12 months period 7/1/98 to 6/30/99. Patients were categorized according to which class of antihypertensive agent they received (CCA, diuretic, beta-blocker or other agents). The frequency of acid suppressive drug use, H2 antagonists (H2A) or proton pump inhibitors (PPI), among the different classes of antihypertensive agents was determined and analyzed using Chi-square. Of the patients receiving antihypertensive drug therapy, the mean (ϮSD) age was 66 (Ϯ14) years old, 43% were males and 58% were Ն 65 years old. Thirty-seven percent of patients were treated with a CCA alone or in combination. The frequency of H2/PPI use was significantly greater in patients receiving a CCA than in patients not receiving a CCA, 24% vs 17%, respectively, p Ͻ 0.0001. Of those not receiving a CCA the frequency of H2/PPI use was 18%, 16%, and 19%, in patients receiving diuretics, beta-blockers and other antihypertensives, respectively. Conclusion: The use of CCA's in hypertensive patients was associated with an increased use of acid suppressive agents. The potential morbidity and financial burden of these findings warrant further investigation.
Key Words: Calcium channel antagonist; diuretics; betablockers; adverse effects G. Grassi, M.L. Stella, S. Vailati, G. Seravalle, M. Ciampa, and G. Mancia. Clinica Medica, University of Milano-Bicocca, Osp. S. Gerardo, Monza; Centro Fisiologia Clinica ed Ipertensione, IRCCS, Milan Istituto Auxologico Italiano, IRCCS, Milan, Italy It is still undetermined whether pharmacological regression of vascular structural changes associated with hypertension depends on the drug-induced blood pressure reduction "per se" or rather on the antihypertensive effects of the drug coupled with its additional properties (e.g., antioxidative effects, vascular selectivity, etc.).
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EFFECTS OF LERCANIDIPINE ON FOREARM AND CALF VASCULAR STRUCTURAL CHANGES IN HYPERTENSION
To clarify this aspect in 24 mild to moderate untreated essential hypertensives (age: 47.3 Ϯ 0.5 years; mean arterial pressure, MAP: 115.4 Ϯ 3.6 mmHg, mean Ϯ SEM), with no other major cardiovascular or non-cardiovascular diseases, we measured beat-to-beat MAP (Finapres), heart rate (HR, EKG), forearm and calf blood flows (FBF, CBF, venous occlusion plethysmography) and calculated forearm and calf vascular resistance (FVR:MAP/FBF,CVR:MAP/CBF respectively). We also evaluated forearm and calf minimal vascular resistance (FVRmin and CVRmin) following 12 min of local ischaemia associated with 2 min of isometric exercise. The entire protocol was performed in the no drug condition and AJH-APRIL 2000 -VOL. 13, NO. 4, PART 2 ORALS: New Drugs 137A repeated following a 6 month treatment with lercanidipine (L, 10 mg/day per os, n ϭ 12) of hydrochlorothiazide (H, 25 mg/day per os, n ϭ 12) accordingly to a double blind design.
L caused a significant (p Ͻ 0.01) reduction in MAP (Ϫ12.9 Ϯ 1.1 mmHg), FVR (Ϫ12.6 Ϯ 1.6 U) and CVR (Ϫ15.1 Ϯ 1.7 U) without affecting HR values. These effects were coupled with a significant reduction in FVRmin (from 3.1 Ϯ 0.3 to 2.0 Ϯ 0.2 U, p Ͻ 0.01) and in CVRmin (from 4.6 Ϯ 0.3 to 3.5 Ϯ 0.3 U, p Ͻ 0.05). In contrast, for similar MAP reduction (Ϫ10.8 Ϯ 1.4 mmHg, p Ͻ 0.01), H caused a slight decrease in FVR and CVR (Ϫ6.5 Ϯ 1.3, Ϫ7.6 Ϯ 1.5 U respectively) without significantly affecting FVRmin and CVRmin.
These data provide evidence that for similar blood pressure reductions only drugs, such as L with additional vasoprotective properties, are capable of favouring a regression of the vascular structural changes associated with hypertension. This implies that the blood pressure reduction "per se" may be not sufficient to cause regression of vascular hypertrophy. Blood pressure control and medication costs are two important parts in antihypertensive drug product selection. Within a therapeutic drug class, acquisition costs many times take precedence over efficacy. The purpose of this study was to evaluate 24 hour blood pressure control and adverse effects in patients with essential hypertension when switched from Amlodipine (A) to Nisoldipine (N). Hypertensive patients stabilized on A 5 mg or 10 mg were monitored over 24 hours with an ambulatory blood pressure monitor (AMBP). The following day the patients were switched to (N) 10 mg (Ն65 yrs old) or 20 mg (Ͻ65 yrs old). (N) dose was adjusted to maintain BP equivalent to (A) dose or Ͻ140/90, whichever was lower. After 8 -16 weeks patients were again monitored with the 24 hour blood pressure monitor. Mean 24 hour, daytime and nighttime blood pressures, diurnal variation, number of dose titrations, significant adverse reactions and cost differences were measured. This study is currently in progress with 48% (11/23) of patients completed. Results thus far have shown no significant difference between (A) and (N) with regards to mean 24 hr AMBP (ϩ1.8 mm Hg/ϩ2.4 mm Hg), daytime (ϩ1.3/ ϩ2.5) and nighttime (ϩ2.6/ϩ2) blood pressures and diurnal variation (10.1%/11.3% vs. 9.1%/11.6%, Sys/Dia (A) vs. (N)). Three dose titrations have occurred and no significant adverse events were reported. AWP for low dose (A) is $1.29/day vs. $0.93 of (N). High dose AWP is $2.50 vs. $0.93 for (A) and (N), respectively. Based on the data obtained thus far, patients taking (A) can be safely and effectively switched to (N). Last Joint National Committee (JNC) recommendations are stricter, especially with hypertensive patients with associated risk factors. Our objective is to determine if the convenience in dosage range in monotherapy could improve hypertensive control.
Victoria Study was designed in order to evaluate the efficacy and safety of Quinapril 40 mg in 22,000 patients treated during 8 weeks.
The study began in March 1999. In November 1999 we obtained the information of 2012 patients, 54% males, 15% diabetics and 10% with cardiovascular disease. Most of them (71%) were previously treated with anti-hypertensive treatment. 1% had controlled sistolic blood pressure (SBP) (Ͻ140 mmHg or Ͻ135 mmHg, depending on the risk factors) and 6% had controlled diastolic blood pressure (DBP) (Ͻ90 mmÇ Hg or Ͻ85 mmHg depending on the risk factors) with mean values of SBP 165 Ϯ 16 and DBP 98 Ϯ 9 (mmHg Ϯ SD). After 2 months of treatment with Quinapril 40 mg, the percentage of controlled blood pressure values (Ͻ140/90 mmHg or 130/85 mmHg) increased up to 28% in SBP and 65% in DBP. Quinapril 40 mg was well tolerated and no relevant adverse events were detected.
We conclude that Quinapril 40 is able to control blood pressure in hypertensive population previously treated and uncontrolled. The number of patients controlled were 65% for DBP and 28% for SBP, in patients previously treated with other anti-hypertensive medication but without reaching the minimum JNC recommendations (Ͻ140/90 mmHg). This multicenter, double-blind study evaluated the efficacy and safety of omapatrilat (OMA), a vasopeptidase inhibitor (VPI), when given in conjunction with hydrochlorothiazide (HCTZ) to subjects unresponsive to HCTZ alone. The study randomized 274 subjects with mild to severe hypertension (seated diastolic blood pressure [SeDBP] 95-120 mm Hg). After a 2-week placebo lead-in period and 4-week HCTZ filter period, subjects with SeDBP 93-100 mm Hg were randomized to receive OMA (10 mg or 20 mg, titrated to 20 mg or 40 mg respectively at week 4 if SeDBP was Ն90 mm Hg) or matching placebo, both in addition to HCTZ 25 mg as
